LPI and 2-ALPI Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 12 studies associated with LPI and 2-ALPI.
Here is a small sampling of LPI and 2-ALPI studies by title:
- Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?
- Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC
- Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer
- Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
- The L-α-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis
Components of the LPI and 2-ALPI Research Dashboard
- Top medical conditions associated with LPI and 2-ALPI
- Proven effects in clinical trials for LPI and 2-ALPI
- Receptors associated with LPI and 2-ALPI
- Individual study details for LPI and 2-ALPI
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - LPI and 2-ALPI
Description of LPI and 2-ALPI
Lysophosphatidylinositol (LPI is an endogenous ligand/agonist for GPR55) and 2-arachidonoyl lysophosphatidylinositol (2-ALPI) are biologically active lipids that are involved in cannabinoid signaling.
Lysophosphatidylinositol and 2-arachidonoyl lysophosphatidylinositol
LPI and 2-ALPI Properties and Effects
Analgesia for inflammation and neuropathic-based pains, Glucose homeostasis, LPI/GPR55 axis may play a role in certain cancer developments and metastasis (i.e., breast cancer, colon cancer, uterine/endometrial cancer)
LPI and 2-ALPI Receptor Binding
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.